OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
August 08, 2025
For the first target addressed in the partnership, the two companies reported the successful delivery of AI-designed, functional antibody leads.
August 07, 2025
Orforglipron showed clinically meaningful results at 72 weeks, after three doses, in a pool of more than 3000 adults.
The investment will expand the company’s manufacturing and packaging capabilities at its Maple Grove, Minn. site, which Bora acquired in 2024 with its acquisition of Upsher-Smith Laboratories.
August 06, 2025
The acquisition expands the CDMO’s small-molecule API development and manufacturing services in the US.
August 05, 2025
Findings from a Phase III study highlight the demonstrated action of donanemab-azbt (brand name Kisunla) in slowing the decline of patients exhibiting early symptomatic Alzheimer’s disease.
August 04, 2025
Radiopharmaceuticals are moving from their standard use of treating superficial tumors into radio drug conjugates that target tumors without impacting other cells in the body.
The program has been transitioned to a permanent pathway that is designed to support innovative tools like artificial intelligence, wearables, and biomarkers in drug development and trials.
The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical portfolios at this year’s AAIC.
August 01, 2025
If action is not taken within 60 days, the White House said it would “deploy every tool in our arsenal” to improve drug pricing practices for American patients.
Help us get a better picture of how new tariffs and trade policy have impacted you and your organization.